nL-TARDB-002

Preclinical

nL-TARDB-002 is one of 7 therapeutic programs targeting Amyotrophic Lateral Sclerosis (ALS). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Amyotrophic Lateral Sclerosis (ALS)Enrolling by invitation

Amyotrophic Lateral Sclerosis (ALS)Preclinical

Enrolling by invitation

Competition

Competitive Landscape

12 competitors in Amyotrophic Lateral Sclerosis (ALS)

#DrugCompanyPhaseTrials

Rilutek

AAzurity Pharmaceuticals

Phase 2

1 2

VHB937

Novartis

Phase 2

1 3

Cromolyn Sodium

UUniversity of California, San Francisco

Phase 2

1 4

XT-150

XXalud Therapeutics, Inc.

Phase 1

1 5

NUZ-001

MMerit E. Cudkowicz, MD

Preclinical

1 6

nL-TARDB-002

Nn-Lorem Foundation

Preclinical

1 7

MTP-101C

UUniversity of Minnesota

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

An Open-label Study of an Experimental Antisense Oligonucleotide Treatment for Amyotrophic Lateral Sclerosis (ALS) Due to TARDBP (TDP-43) Genetic Mutation

Enrolling by invitation·Nn-Lorem Foundation·Preclinical·NCT07703462·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nL-TARDB-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for nL-TARDB-002. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — n-Lorem Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Nn-Lorem Foundation

nL-TARDB-002

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

References

Drug Info

Quick Facts

Related News